MEREO BIOPHARMA GROUP PLC Increase Decrease In Operating Lease Liability
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase Decrease In Operating Lease Liability of -$200.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC increase decrease in operating lease liability for the quarter ending 2026-06-30 was $1.00K.
- MEREO BIOPHARMA GROUP PLC increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$201.00K.
- MEREO BIOPHARMA GROUP PLC increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$194.00K.
- MEREO BIOPHARMA GROUP PLC increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$188.00K.
- MEREO BIOPHARMA GROUP PLC increase decrease in operating lease liability for fiscal 2025 was -$743.00K.
- MEREO BIOPHARMA GROUP PLC increase decrease in operating lease liability for fiscal 2024 was -$654.00K.
- MEREO BIOPHARMA GROUP PLC increase decrease in operating lease liability for fiscal 2023 was -$578.00K.
- MEREO BIOPHARMA GROUP PLC increase decrease in operating lease liability for fiscal 2022 was -$878.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$200.00K 10-Q · filed 2026-08-11 | -$394.00K derived: sum of 3 quarters · filed 2026-08-11 | -$582.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$201.00K 10-Q · filed 2026-05-12 | -$395.00K derived: sum of 2 quarters · filed 2026-05-12 | -$583.00K derived: sum of 3 quarters · filed 2026-05-12 | -$774.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$382.00K derived: sum of 2 quarters · filed 2026-03-19 | -$573.00K derived: sum of 3 quarters · filed 2026-08-11 | -$743.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$188.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$379.00K derived: sum of 2 quarters · filed 2026-08-11 | -$549.00K 10-Q · filed 2025-11-10 | -$719.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$191.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$361.00K 10-Q · filed 2026-08-11 | -$531.00K derived: sum of 3 quarters · filed 2026-08-11 | -$699.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$170.00K 10-Q · filed 2026-05-12 | -$340.00K derived: sum of 2 quarters · filed 2026-05-12 | -$508.00K derived: sum of 3 quarters · filed 2026-05-12 | -$668.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$338.00K derived: sum of 2 quarters · filed 2026-03-19 | -$498.00K derived: sum of 3 quarters · filed 2026-03-19 | -$654.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | -$168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$328.00K derived: sum of 2 quarters · filed 2025-11-10 | -$484.00K 10-Q · filed 2025-11-10 | -$634.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$316.00K 10-Q · filed 2025-08-12 | -$466.00K derived: sum of 3 quarters · filed 2025-08-12 | -$614.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$156.00K 10-Q · filed 2025-05-13 | -$306.00K derived: sum of 2 quarters · filed 2025-05-13 | -$454.00K derived: sum of 3 quarters · filed 2025-05-13 | -$598.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$298.00K derived: sum of 2 quarters · filed 2025-03-26 | -$442.00K derived: sum of 3 quarters · filed 2025-03-26 | -$578.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | -$148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$292.00K derived: sum of 2 quarters · filed 2024-11-12 | -$428.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$280.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$136.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$878.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |